The proliferation of GLP-1 weight loss drugs is affecting the US cannabis industry. Dispensaries are noticing changes in consumption and revising their business strategies.
GLP-1 drugs are changing the market
According to information Reuters, The popularity of GLP-1 weight control drugs such as Ozempic and Wegovy is growing in the US. This has an impact on the cannabis market, as the drugs can reduce appetite and change consumer habits.
Some cannabis dispensaries report a decrease in demand for appetite-stimulating products. They are beginning to adapt their product range to meet new customer preferences.
Reaction of cannabis dispensaries
Cannabis dispensaries in the US are analysing trends and reviewing their offerings. They are considering expanding the range of products that do not affect appetite or have other therapeutic effects.
Some companies are studying the behaviour of customers taking GLP-1 drugs to better meet their needs. This may lead to new products on the market.
Impact on the industry
Changes in cannabis consumption may affect the profits of dispensaries and producers. The industry is monitoring the situation and looking for ways to adapt to the new reality.
Experts note that this is only the beginning of the changes, and further developments will depend on the popularity of GLP-1 drugs.
Ukrainian
English